Coley's toxins

Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Friday, December 2, 2022
Therapy, Ernest, IND, Poster, Society, Patient, Cancer, Biology, COVID-19, ETB (company), Coley's toxins, Safety, ASH, Pharmaceutical industry, Molecule

Molecular Templates will also participate in one-on-one meetings at the 64th American Society of Hematology (ASH) Annual Meeting which will take place December 10 December 13, 2022 at the Ernest N. Morial Convention Center in New Orleans, LA.

Key Points: 
  • Molecular Templates will also participate in one-on-one meetings at the 64th American Society of Hematology (ASH) Annual Meeting which will take place December 10 December 13, 2022 at the Ernest N. Morial Convention Center in New Orleans, LA.
  • In-person and virtual meetings may be scheduled directly with Molecular Templates.
  • Forward-looking statements are not guarantees of future performance and involve risks and uncertainties.
  • Any forward-looking statements contained in this press release speak only as of the date hereof, and Molecular Templates specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI’s 5th Annual HealthCONx Conference and Piper Sandler’s 34th Annual Healthcare Conference

Retrieved on: 
Wednesday, November 23, 2022
COVID-19, Conference, Doctor of Philosophy, IND, Patient, ETB, Evercore, ETB (company), Piper, Q&A, Cancer, Therapy, Biology, Coley's toxins, Safety, Pharmaceutical industry, Molecule

Highlighting positive incremental data, the chats will comprise a review of the de-immunized next-generation ETB scaffold and programs.

Key Points: 
  • Highlighting positive incremental data, the chats will comprise a review of the de-immunized next-generation ETB scaffold and programs.
  • One-on-one meetings may be scheduled with banking representatives of Evercore ISI or Piper Sandler, respectively, or directly with Molecular Templates.
  • Forward-looking statements are not guarantees of future performance and involve risks and uncertainties.
  • Any forward-looking statements contained in this press release speak only as of the date hereof, and Molecular Templates specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

Molecular Templates, Inc. to Present Interim Data and Host R&D Day at The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Retrieved on: 
Friday, November 4, 2022
ETB, Private Securities Litigation Reform Act, Therapy, 2021 Essex County Council election, Coley's toxins, Boston Convention and Exhibition Center, Biology, GLOBE, Safety, Webcast, IND, COVID-19, Patient, Nasdaq, Immunotherapy, The Society, Annual general meeting, Q&A, PD-L1, ETB (company), Forward-looking statement, Development, R, Technology, SEC, SITC, Convention center, Cancer, Pharmaceutical industry, Molecule

The event will be webcasted and take place 11:30am 12:30pm ET Friday, November 11, 2022, at the Boston Convention Center during SITCs 37th Annual Meeting.

Key Points: 
  • The event will be webcasted and take place 11:30am 12:30pm ET Friday, November 11, 2022, at the Boston Convention Center during SITCs 37th Annual Meeting.
  • A live Q&A session will follow the presentation.
  • Molecular Templates is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics.
  • Forward-looking statements are not guarantees of future performance and involve risks and uncertainties.

Molecular Templates Announces Participation in Four Upcoming Conferences

Retrieved on: 
Wednesday, August 31, 2022
COVID-19, Cancer, Safety, IND, Morgan Stanley, Coley's toxins, SEC, Antibody-drug conjugate, GLOBE, Control, Conference, Biology, Nasdaq, Therapy, ETB (company), Private Securities Litigation Reform Act, Forward-looking statement, Patient, Pharmaceutical industry, Molecule

AUSTIN, Texas, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM, Molecular Templates or MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), will participate in the following September 2022 conferences.

Key Points: 
  • AUSTIN, Texas, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM, Molecular Templates or MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), will participate in the following September 2022 conferences.
  • One-on-one meetings may be scheduled via conference representatives or directly with Molecular Templates.
  • Molecular Templates disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Acts Safe Harbor for forward-looking statements.
  • Any forward-looking statements contained in this press release speak only as of the date hereof, and Molecular Templates specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

Molecular Templates’ Presentations at the 2022 ASCO Annual Meeting Demonstrate Advancement in PD-L1 and HER2 Programs

Retrieved on: 
Monday, June 6, 2022
Large-cell lung carcinoma, DLT, Biology, Society, Coley's toxins, Safety, Forward-looking statement, CEO, Breast cancer, ASCO, Dermatitis, Nasdaq, IND, Therapy, HER2, American Society of Clinical Oncology, GLOBE, Patient, Doctor of Philosophy, Private Securities Litigation Reform Act, PD-1, COVID-19, Infrared spectroscopy correlation table, CSO, PD-L1, SEC, ETB (company), ETB, Serum, PD, NSCLC, Cancer, Pharmaceutical industry, Vaccine, Palladium, Molecule

Copies of the posters presented at ASCO can be found in the Investors section of Molecular Templates corporate website under Presentations .

Key Points: 
  • Copies of the posters presented at ASCO can be found in the Investors section of Molecular Templates corporate website under Presentations .
  • ETBs offer novel biology with the potential to drive unique clinical outcomes, even against well-explored targets, said Eric Poma, Ph.D., CEO and CSO of Molecular Templates.
  • Treatment is on-going in the 32 mcg/kg cohort with no dose-limiting toxicities (DLTs) observed to date in the third cohort.
  • Molecular Templates is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics.

Molecular Templates, Inc. Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 12, 2022
Sarah Cannon Research Institute, Risk, MTD, HER2, Doctor of Philosophy, Neoplasm, TIGIT, Private Securities Litigation Reform Act, Coley's toxins, Nasdaq, Tumor microenvironment, Breast cancer, Capillary leak syndrome, IC50, Patient, Investment, Poster, Biology, AACR, TME, PD-1, Abstract (summary), Society, COVID-19, ETB (company), American Society of Clinical Oncology, Bristol Myers Squibb, HLA, NSCLC, PD-L1, DLT, IND, Takeda, Index (publishing), Board, Forward-looking statement, General counsel, Safety, Board of directors, ASCO, Large-cell lung carcinoma, Cardiotoxicity, CLS, Therapy, PD, Infrared spectroscopy correlation table, SEC, Dermatitis, Bone disease, Cancer, GLOBE, Regulatory T cell, ETB, Fine chemical, Pharmaceutical industry, Iron ore, Vaccine, Aluminium, Medical imaging, Molecule

AUSTIN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc.(Nasdaq: MTEM, Molecular Templates, or MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the first quarter of 2022.

Key Points: 
  • AUSTIN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc.(Nasdaq: MTEM, Molecular Templates, or MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the first quarter of 2022.
  • MTEM is opening new sites for the Phase 1 study and anticipates enrollment beginning in the second quarter of 2022.
  • Revenues for the first quarter of 2022 were $8.5 million, compared to $3.2 million for the same period in 2021.
  • For more details on MTEMs financial results for the first quarter 2022, refer to Form 10Q filed with the SEC.

Molecular Templates’ Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2022 Highlight Potential of ETB Approach

Retrieved on: 
Tuesday, April 12, 2022
MMAF, CEO, Cytomegalovirus, Cancer, Pharmacodynamics, IND, Dermatitis, COVID-19, Population, Toxicity, PD-1, CCL3, PD-L1, Coley's toxins, Private Securities Litigation Reform Act, Doctor of Philosophy, GLOBE, Regulatory T cell, Patient, American Association for Cancer Research, TME, Infrared spectroscopy correlation table, CD117, Neoplasm, AST, Ernest, NSCLC, CSO, Technology, CMV, HLA-A*02, Nasdaq, Antigen, DLT, ETB (company), SEC, Forward-looking statement, IL-6, Investor, CCL4, LPS, Biology, ETB, Large-cell lung carcinoma, Tumor microenvironment, Safety, CLS, American Association, HLA, Capillary leak syndrome, AACR, Therapy, PD, Pharmaceutical industry, Vaccine, Palladium, Gasoline, Molecule

Copies of the posters presented at AACR can be found in the Investors section of Molecular Templates website under Presentations .

Key Points: 
  • Copies of the posters presented at AACR can be found in the Investors section of Molecular Templates website under Presentations .
  • Pharmacodynamic (PD) effects including monocyte and myeloid-derived suppressor cell depletion and T cell activation have been observed in the majority of patients.
  • This approach is currently being tested clinically with MT-6402, a PD-L1 targeted ETB that delivers an HLA-A2 antigen derived from cytomegalovirus (CMV).
  • Molecular Templates has developed CD117 targeting ETBs that may have potential uses in myeloablation or in oncology.

Molecular Templates to Host Webinar on a Unique Approach to Immuno-Oncology for Solid Tumors

Retrieved on: 
Friday, April 8, 2022
Dana–Farber Cancer Institute, Private Securities Litigation Reform Act, Hematology, University, University of Tennessee, Therapy, Forward-looking statement, ETB (company), IND, CMV, Research, SEC, The, Cancer, Internal medicine, ETB, MD, Sarah Cannon Research Institute, Safety, Biology, Coley's toxins, Oncology, Nasdaq, COVID-19, GLOBE, Physician, Tulane University, PD-L1, Patient, Pharmaceutical industry, Vaccine, Medicine, Molecule, PLLC

AUSTIN, Texas, April 08, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that it will host a webinar on a unique approach to immuno-oncology for solid tumors on Wednesday, April 13, 2022 at 8:00 am Eastern Time.

Key Points: 
  • The webinar will feature a presentation from medical expert David Spigel, MD, of the Sarah Cannon Research Institute, who will discuss Molecular Templates program, MT-6402 (targeting PD-L1), and the implications of thePhase 1 data as it relates to treating patients with a variety of PD-L1-expressing solid tumors.
  • MT-6402 is the first of the Companys 3rd generation ETBs to enter the clinic.
  • The Molecular Templates management team will provide a brief company update.
  • Molecular Templates is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics.

Molecular Templates, Inc. Reports Fourth Quarter 2021 Financial Results

Retrieved on: 
Monday, March 28, 2022
BCMA, Cardiotoxicity, Private Securities Litigation Reform Act, Risk, Therapy, Investment, CD45, Forward-looking statement, ETB (company), Board, IND, MTD, AACR, SEC, Tumor microenvironment, Infrared spectroscopy correlation table, Research, American Association, PD, CLS, Patient, Cancer, ETB, Food, NSCLC, Neoplasm, 2021 Essex County Council election, Capillary leak syndrome, Index (publishing), Association, Safety, Review, DLT, Biology, Director, American Association for Cancer Research, General counsel, TIGIT, Coley's toxins, Vertex, Nasdaq, Doctor of Philosophy, COVID-19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Bone disease, Bristol Myers Squibb, Breast cancer, PD-L1, Large-cell lung carcinoma, Vaccine, Iron ore, Pharmaceutical industry, Palladium, Dietary supplement, Molecule, Takeda

AUSTIN, Texas, March 28, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc.(Nasdaq: MTEM, Molecular Templates, or MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the fourth quarter of 2021.

Key Points: 
  • AUSTIN, Texas, March 28, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc.(Nasdaq: MTEM, Molecular Templates, or MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the fourth quarter of 2021.
  • The net loss attributable to common shareholders for the fourth quarter of 2021 was $10.2 million, or $0.18 per basic and diluted share.
  • Revenues for the fourth quarter of 2021 were $18.0 million, compared to $3.5 million for the same period in 2020.
  • Revenues for the fourth quarter of 2021 were comprised of revenues from collaborative research and development agreements with Vertex and Bristol Myers Squibb.

Molecular Templates Strengthens Board of Directors and Management Team

Retrieved on: 
Wednesday, March 2, 2022
Associate, Industry, Clinical pharmacology, Corporation, ETB (company), Regulatory science, Lawyer, Biology, Board, COVID-19, Medicine, CSO, Partnership, Nasdaq, Hematology, Private Securities Litigation Reform Act, Blank Rome, Forward-looking statement, General counsel, Rutgers School of Management and Labor Relations, Pfizer, Gruia, Company, SEC, CEO, Rutgers Law School, Rutgers Journal of Law & Public Policy, Regulatory affairs, Neoplasm, IND, Pharmacia, Boston University, Novartis, Coley's toxins, Patient, The arts, Immunotherapy, Mammography, Safety, Society of American Business Editors and Writers, Board of directors, Paris Descartes University, Cancer, Public policy, René, ETB, Sanofi, GLOBE, Therapy, Pharmaceutical industry, Management, Law, Director, Molecule, Biostatistics, Toxicology, History

AUSTIN, Texas, March 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced the appointment of Gabriela Gruia, M.D., to its Board of Directors and the promotion of Megan Filoon to General Counsel.

Key Points: 
  • Dr. Gruia brings a wealth of industry knowledge to our Board of Directors, said Barry Selick, Ph.D., Chairman of the Board of Molecular Templates.
  • Dr. Gruia stated, I am pleased to have the opportunity to join the Molecular Templates Board of Directors.
  • Megan Filoon joined Molecular Templates in May 2018 as Corporate Counsel and most recently served as Vice President, Legal.
  • Megans diverse and extensive legal expertise and her track record of success make her a great addition to the MTEM senior management team, said Eric Poma, CEO and CSO of Molecular Templates.